Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 12 VISTA-101 Clinical Trial and Corporate Activities
| KA Stock | 0.48 0.04 7.69% |
About 51% of Kineta's investor base is interested to short. The analysis of the overall investor sentiment regarding Kineta Inc suggests that many traders are impartial. The current market sentiment, together with Kineta's historical and current headlines, can help investors time the market. In addition, many technical investors use Kineta Inc stock news signals to limit their universe of possible portfolio assets.
Kineta |
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety...
Read at globenewswire.com
 |
Kineta Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Kineta can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Kineta Fundamental Analysis
We analyze Kineta's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kineta using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kineta based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Kineta is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Kineta Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kineta stock to make a market-neutral strategy. Peer analysis of Kineta could also be used in its relative valuation, which is a method of valuing Kineta by comparing valuation metrics with similar companies.
Peers
Kineta Related Equities
| PTIX | Protagenic Therapeutics | 4.00 | ||||
| ANEB | Anebulo Pharmaceuticals | 0.72 | ||||
| XOMAO | XOMA | 0.35 | ||||
| LUMO | Lumos Pharma | 0.23 | ||||
| DMAC | DiaMedica Therapeutics | 1.30 | ||||
| MOLN | Molecular Partners | 1.47 | ||||
| ALVR | Allovir | 2.17 | ||||
| RZLT | Rezolute | 2.18 | ||||
| MLYS | Mineralys Therapeutics, | 2.22 | ||||
| PHVS | Pharvaris | 3.26 | ||||
| ANTX | AN2 Therapeutics | 3.38 | ||||
| TPST | Tempest Therapeutics | 3.61 | ||||
| PEPG | PepGen | 3.63 | ||||
| INKT | Mink Therapeutics | 6.45 | ||||
| DYAI | Dyadic International | 8.59 | ||||
| SILO | Silo Pharma | 8.70 | ||||
| CADL | Candel Therapeutics | 8.74 | ||||
| FBRX | Forte Biosciences | 18.10 |
Complementary Tools for Kineta Stock analysis
When running Kineta's price analysis, check to measure Kineta's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kineta is operating at the current time. Most of Kineta's value examination focuses on studying past and present price action to predict the probability of Kineta's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kineta's price. Additionally, you may evaluate how the addition of Kineta to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |